Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $1.8 million.

  • Altimmune's Non Operating Income fell 400.62% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 3024.14%. This contributed to the annual value of $8.1 million for FY2024, which is 843.36% up from last year.
  • Per Altimmune's latest filing, its Non Operating Income stood at $1.8 million for Q3 2025, which was down 400.62% from $776000.0 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Non Operating Income registered a high of $2.4 million during Q1 2024, and its lowest value of -$306000.0 during Q3 2021.
  • For the 5-year period, Altimmune's Non Operating Income averaged around $1.2 million, with its median value being $1.6 million (2025).
  • As far as peak fluctuations go, Altimmune's Non Operating Income crashed by 55835.22% in 2021, and later surged by 187037.04% in 2022.
  • Altimmune's Non Operating Income (Quarter) stood at -$81000.0 in 2021, then soared by 1870.37% to $1.4 million in 2022, then surged by 38.21% to $2.0 million in 2023, then fell by 14.93% to $1.7 million in 2024, then rose by 9.43% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $776000.0 for Q2 2025, and $1.6 million during Q1 2025.